CClinicalTrials.gg
Status unknownNCT05744089Updated Feb 28, 2023

Home Management of Simple Hydromorphone PCA Pump Mode

An interventional study of PCA pump in Cancer Pain, Tumor, Solid and Carcinoma, sponsored by The First Affiliated Hospital of Xinxiang Medical College. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-28.

Sponsored by The First Affiliated Hospital of Xinxiang Medical College · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2023), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This prospective observational study will evaluate the efficacy and adverse effects of a "simple hydromorphone PCA pump model", which is a rapid titration followed by a convenient maintenance technique, to treat home cancer patients with severe or critical cancer pain or refractory cancer pain.

Read the detailed description

This is a single-arm multicenter study that will involve 8-10 centers and 50 cases in total. A better pumping mode was discovered through repeated optimization and adjustment of PCA pump parameters, ensuring the unity of convenience, safety, and flexibility: on the one hand, it is convenient for clinicians to set up and adjust the pump quickly; on the other hand, it is also convenient for patients to control at home; thus, it solves the complex pumping and dosing problems. Nearly 20 patients with severe cancer pain or a cancer pain crisis were treated using this model, and the control satisfaction rate was 100% in each case.

The purpose of this study is to:

  1. Main objective: To explore the efficacy and adverse effects of a simple hydromorphone PCA pump model, i.e., rapid titration followed by maintenance, for the treatment of patients with severe cancer pain or cancer pain crisis or refractory cancer pain in home cancer patients.
  2. Exploratory purpose: To screen sensitive indicators for cancer pain assessment and efficacy monitoring by Ella fully automated microfluidic ELISA system, and to explore the mechanism of action of pain-causing substances in cancer pain initially.
02

Conditions studied

  • Cancer Pain
  • Tumor, Solid
  • Carcinoma

Browse trials for

03

In context

Cancer Pain

338 studies on the registry are indexed under Cancer Pain; 71 are open to participants now.

This study's planned enrollment of 50 is below the median of 60 across 254 interventional studies indexed under Cancer Pain.

Browse Cancer Pain studies →

Lead sponsor

The First Affiliated Hospital of Xinxiang Medical College is the lead sponsor of 41 studies on the registry; 37 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Age ≥ 18 years.
  2. Patients with pathologically confirmed malignant solid tumors; patients with advanced metastatic cancer assessed by imaging
  3. Patients with persistent cancer pain and an NRS score of ≥7 in the past 24 hours; or patients with refractory pain
  4. Patients who have not received radiation therapy within 7 days prior to randomization and trial
  5. Patients without cognitive impairment or mental illness.
  6. the patient is able to complete the survey form
  7. Patients can correctly understand and cooperate with the healthcare provider's medication instructions.
  8. ECOG-PS ≤ 3 points.
  9. Subjects voluntarily and signed the informed consent form.
  10. Failure of antineoplastic treatment or refusal of antineoplastic treatment at home or community hospital.

Exclusion criteria

Exclusion Criteria:

  1. Patients with a diagnosis of non-cancerous pain or pain of unknown origin.
  2. Patients receiving inpatient antineoplastic therapy.
  3. patients with paralytic intestinal obstruction
  4. patients with opioid allergy.
  5. abnormal and clinically significant laboratory results, such as creatinine ≥ 2 times the upper limit of normal, ALT or AST ≥ 2.5 times the upper limit of normal (≥ 5 times the upper limit of normal in patients with liver metastases or primary hepatocellular carcinoma), or grade C liver function Child
  6. Uncontrollable nausea and vomiting.
  7. Use of monoamine oxidase inhibitors within 14 days prior to randomization.
  8. pregnant or lactating women; subjects with a planned pregnancy within 1 month of trial (also includes male subjects)
  9. Patients with alcohol abuse.
  10. Other diseases and conditions that, in the opinion of the investigator, preclude enrollment.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Cancer patients suffering severe or critically painful

    Device: PCA pump

Interventions

  • DevicePCA pump

    simple hydromorphone PCA pump model, which is a rapid titration followed by a convenient maintenance technique, to treat home cancer patients with severe or critical cancer pain or refractory cancer pain.

06

What researchers measure

Primary outcomes

  1. Pain score

    Subjects self-assess on the NRS pain rating scale in the subject log sheet, where subjects assess the level of cancer pain experienced in the past 24 hours.

    Time frame: 10 days

  2. The frequency of paroxysmal pain

    Paroxysmal pain is defined as a sudden and transient pain exacerbation that occurs spontaneously or triggered by some predictable or unpredictable factors under the premise of relatively stable background pain control and adequate application of analgesic drugs. The onset, duration and number of cancer eruption pain episodes were recorded by the subjects in the logbook at the time of the episode.

    Time frame: 10 days

  3. Life quality

    The WHOQOL-BREF is a 26-item self-assessment questionnaire that investigates the last two weeks of physical health, mental health, social relationships, and environment. It allows for a reliable, valid and brief assessment of quality of life. In this study, the psychological domain (6 items) was used to represent the psychological aspects of quality of life.

    Time frame: 10 days

  4. The evaluation of PCA home feasibility

    During the trial, monitoring the number of occurrences of PCA blockage and reflux in patients, as well as will record the number of times they seek help from healthcare professionals in case of PCA pump-related problems that cannot be solved by themselves.

    Time frame: 10 days

Secondary outcomes

  1. The concentration of immune-related cytokines

    the content of PD 1, IL-2, IL-6, STING, CD3+, CD4+, IFN-1and IFN-γ in patients' serum

    Time frame: 10 days

07

Study locations

1 site
  • The First Affiliated Hospital of Xinxiang Medical University
    Xinxiang, Henan 453100, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05744089
Lead sponsor
The First Affiliated Hospital of Xinxiang Medical College
Responsible party
Sponsor
First posted
Feb 24, 2023
Start date
Feb 2023 (estimated)
Primary completion
Feb 2024 (estimated)
Completion
Feb 2025 (estimated)
Last update
Feb 28, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion